Evidence map›Paper›PMID 41246453›Full record

ArticleResearch and practice in thrombosis and haemostasis2025

Large deletions in the

Ilja Oomen, Amal Abdi, Linda Broer, Ricardo M Camelo, Fábia M R A Callado, Luany E M Carvalho, Ilenia L Calcaterra, Manuel Carcao, Giancarlo Castaman, Jeroen C J Eikenboom and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Ilja OomenDepartment of Pediatric Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Amal AbdiDepartment of Pediatric Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Linda BroerDepartment of Internal Medicine, Laboratory for Population Genomics, Human Genomics Facility, Erasmus University Medical Center, Rotterdam, the Netherlands.
Ricardo M CameloDepartment of Internal Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Fábia M R A CalladoFundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, Brazil.
Luany E M CarvalhoCentro de Hematologia e Hemoterapia do Ceará (HEMOCE), Fortaleza, Brazil.
Ilenia L CalcaterraDepartment of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
Manuel CarcaoDepartment of Pediatrics, Division of Hematology/Oncology, Hospital for Sick Children, Toronto, Canada.
Giancarlo CastamanDepartment of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
Jeroen C J EikenboomDepartment of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.
Kathelijn FischerDepartment of Hematology, Center for Benign Hematology, Thrombosis and Hemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht, the Netherlands.
Vivian K B FrancoCentro de Hematologia e Hemoterapia de Santa Catarina (HEMOSC), Florianópolis, Brazil.
Judy GeisslerDepartment of Blood Cell Research, Sanquin Research, Amsterdam, the Netherlands.
Taco W KuijpersDepartment of Blood Cell Research, Sanquin Research, Amsterdam, the Netherlands.
Frank W G LeebeekDepartment of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
David LillicrapDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
Cláudia S LorenzatoCoagulopathy Clinic, Hemocentro do Paraná (HEMEPAR), Curitiba, Brazil.
Maria Elisa MancusoCenter for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Davide MatinoDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Matteo N D Di MinnoDepartment of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
Aomei MoDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
Alex B MohsenyDepartment of Pediatrics, Leiden University Medical Center, Leiden, the Netherlands.
Sietse Q NagelkerkeDepartment of Blood Cell Research, Sanquin Research, Amsterdam, the Netherlands.
Johannes OldenburgInstitute of Experimental hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany.
Suely Meireles RezendeDepartment of Internal Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Georges-Etienne RivardMolecular Diagnostic Laboratory, CHU Sainte-Justine, Montréal, Québec, Canada.
Natalia RydzDivision of Hematology, Department of Medicine, University of Calgary, Calgary, Canada.
Saskia E M ScholsDepartment of Hematology, Radboud university medical center, Nijmegen, the Netherlands.
Michael W T TanckDepartment of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
Jan VoorbergDepartment of Molecular Hematology, Sanquin Research, Amsterdam, the Netherlands.
Karin FijnvandraatDepartment of Pediatric Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Samantha C GouwDepartment of Pediatric Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
International GO-ITI Steering Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune tolerance induction (ITI) is the only treatment to eradicate inhibitors in people with severe hemophilia A (SHA). Successful ITI restores factor VIII (FVIII) tolerance. ITI is demanding and successful in approximately 70% of people. Objectives: Identifying predictors of ITI outcome is essential to guide clinical decision making. We aimed to identify genetic predictors of ITI success in people with SHA and inhibitors who underwent ITI. Methods: This observational multicenter study included people with SHA who underwent ITI, between 2015 and 2023. Clinical and patient data, including FVIII gene ( Results: Of 204 participants, 147 (72.1%) achieved ITI success. The majority (52.0%) of participants had Conclusion: Our study of 204 people with SHA identified

Indexed as

factor VIIIgenetic variationhemophilia Aimmune tolerancetreatment outcome

Identifiers

PMID41246453
PMCPMC12616064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.